FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Levine

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sameer Parpia; Lehana Thabane; Timothy J Whelan; Jim A Julian; Mark N Levine
Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study.
Laurie M Elit; Paul Hoskins; Denise H Julian; Jim A Julian; Agnes Y Lee; Patricia C Y Liaw; Sameer Parpia; Laura L Swystun; Mark N Levine
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.
Hsien-Yeang Seow; Anne Snider; Patrick Whelan; Rebecca Y Xu; Kathryn Cowan; Brenda Kowaleski; Mark N Levine; Barbara Lysakowski; Andrew Arnold
Funding oncology clinical trials: are cooperative group trials sustainable?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Levine (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sameer Parpia; Lehana Thabane; Timothy J Whelan; Jim A Julian; Mark N Levine
Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study.
BMC medical research methodology 2013;13():44.
2012: Laurie M Elit; Paul Hoskins; Denise H Julian; Jim A Julian; Agnes Y Lee; Patricia C Y Liaw; Sameer Parpia; Laura L Swystun; Mark N Levine
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.
Thrombosis research 2012;130(6):894-900.
2012: Hsien-Yeang Seow; Anne Snider; Patrick Whelan; Rebecca Y Xu; Kathryn Cowan; Brenda Kowaleski; Mark N Levine; Barbara Lysakowski; Andrew Arnold
Funding oncology clinical trials: are cooperative group trials sustainable?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(13):1456-61.
2011: Frances P O'Malley; Lois E Shepherd; Dongsheng Tu; Irene L Andrulis; Vivien H C Bramwell; S Chia; D Huntsman; Mark N Levine; Kathleen I Pritchard
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
Breast cancer research and treatment 2011;128(2):401-9.
2011: Laurie Elit; Mark N Levine; Jim A Julian; John Sellors; Alice Lytwyn; Sylvia Chong; James B Mahony; Chushu Gu; Terri Finch; Luiz C Zeferino
Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia : a randomized trial in Canada and Brazil.
Cancer 2011;117(7):1438-45.
2010: Som D Mukherjee; Gregory Pond; Laura L Swystun; Jian-Guo Wang; Mark N Levine; Nigel Mackman; Patricia C Y Liaw
Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.
Pathophysiology of haemostasis and thrombosis 2010;37(2-4):88-97.
2009: Frances P O'Malley; S Chia; Dongsheng Tu; Lois E Shepherd; Mark N Levine; Vivien H C Bramwell; Irene L Andrulis; Kathleen I Pritchard
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
Journal of the National Cancer Institute 2009;101(9):644-50.
2008: Ian S Dayes; Mark N Levine; Jim A Julian; Kathleen I Pritchard; David P D'Souza; Lyn Kligman; Donnalue Reise; Jennifer A Wiernikowski; L Bonilla; Timothy J Whelan
Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial.
Breast cancer research and treatment 2008;110(2):337-42.
2008: Marko Simunovic; Charles Goldsmith; Lehana Thabane; Robin McLeod; Franco Denardi; Timothy J Whelan; Mark N Levine
The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery.
BMC surgery 2008;8():4.
2007: Gary H Lyman; Alok A Khorana; Anna Falanga; Daniel L Clarke-Pearson; Christopher Flowers; Mohammad Jahanzeb; Ajay K Kakkar; Nicole Kuderer; Mark N Levine; Howard Liebman; David S Mendelson; Gary E Raskob; Mark R Somerfield; Paul Thodiyil; David Trent; Charles W Francis
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5490-505.
2007: Mark N Levine
Adjuvant therapy and thrombosis: how to avoid the problem?
Breast (Edinburgh, Scotland) 2007;16 Suppl 2():S169-74.
2007: James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gordon Okawara; Mark N Levine
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1027-32.
2006: Mark N Levine; Timothy Whelan
Adjuvant chemotherapy for breast cancer--30 years later.
The New England journal of medicine 2006;355(18):1920-2.
2006: Kathleen I Pritchard; Lois E Shepherd; Frances P O'Malley; Irene L Andrulis; Dongsheng Tu; Vivien H C Bramwell; Mark N Levine
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
The New England journal of medicine 2006;354(20):2103-11.
2006: Agnes Y Y Lee; Mark N Levine; Gregory Butler; Carolyn Webb; Lorrie Costantini; Chushu Gu; Jim A Julian
Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1404-8.
2006: James R Wright; Sarah Bouma; Ian S Dayes; Jonathan Sussman; Marko R Simunovic; Mark N Levine; Timothy J Whelan
The importance of reporting patient recruitment details in phase III trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):843-5.
2006: Eva Grunfeld; Mark N Levine; Jim A Julian; Douglas Coyle; Barbara Szechtman; Doug Mirsky; Shailendara Verma; Susan Dent; Carol Sawka; Kathleen I Pritchard; David Ginsburg; Marjorie Wood; Timothy Whelan
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):848-55.
2005: Mark N Levine; Kathleen I Pritchard; Vivien H C Bramwell; Lois E Shepherd; Dongsheng Tu; Nancy Paul
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5166-70.
2005: Michael J Kovacs; Mark N Levine; Michael Keeney; Karen MacKinnon; Agnes Y Y Lee
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients.
Thrombosis and haemostasis 2005;93(6):1185-8.
2005: Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2123-9.
2004: James R Wright; Timothy J Whelan; Susan Schiff; Sacha Dubois; Dauna Crooks; Patricia T Haines; Diane DeRosa; Robin S Roberts; Amiram Gafni; Kathleen Pritchard; Mark N Levine
Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4312-8.
2004: Marko Simunovic; Craig A Paterson; Angela J Coates; James R Wright; Mark N Levine
Pilot study of the quality initiative in rectal cancer strategy.
Diseases of the colon and rectum 2004;47(10):1594-8.
2004: Mark N Levine; Gary E Raskob; Rebecca J Beyth; Clive Kearon; Sam Schulman
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest 2004;126(3 Suppl):287S-310S.
2003: Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
The New England journal of medicine 2003;349(2):146-53.
2003: Agnes Y Y Lee; Mark N Levine
Venous thromboembolism and cancer: risks and outcomes.
Circulation 2003;107(23 Suppl 1):I17-21.
2003: Mark N Levine
Can we optimise treatment of thrombosis?
Cancer treatment reviews 2003;29 Suppl 2():19-22.
2003: Mark N Levine; Agnes Y Y Lee
Risk assessment and primary VTE prevention in the cancer patient.
Pathophysiology of haemostasis and thrombosis 2003;33 Suppl 1():36-41.
2002: Mark N Levine
Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer.
Cancer treatment reviews 2002;28(3):145-9.
2002: Nancy M Heddle; Morris A Blajchman; Ralph M Meyer; Jeff H Lipton; Irwin R Walker; Graham D Sher; Lorrie A Constantini; Bruce Patterson; Robin S Roberts; Kevin E Thorpe; Mark N Levine
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.
Transfusion 2002;42(5):556-66.
2001: Mark N Levine
Management of thromboembolic disease in cancer patients.
Haemostasis 2001;31 Suppl 1():68-9.
2001: Mark N Levine; Gary E Raskob; S Landefeld; C Kearon
Hemorrhagic complications of anticoagulant treatment.
Chest 2001;119(1 Suppl):108S-121S.
1999: Agnes Y Y Lee; Jim A Julian; Mark N Levine; Jeffrey I Weitz; Clive Kearon; Philip S Wells; Jeffrey S Ginsberg
Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis.
Annals of internal medicine 1999;131(6):417-23.
1998: Mark N Levine; Gary E Raskob; S Landefeld; C Kearon
Hemorrhagic complications of anticoagulant treatment.
Chest 1998;114(5 Suppl):511S-523S.
1998: Mark N Levine; Vivien H C Bramwell; Kathleen I Pritchard; BD Norris; Lois E Shepherd; Hakam Abu-Zahra; Brian Findlay; David Warr; D Bowman; J Myles; Andrew Arnold; Theodore A Vandenberg; R MacKenzie; J Robert; Jon Ottaway; M Burnell; C K Williams; Dongsheng Tu
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2651-8.
1998: George Browman; TE Newman; E Ann Mohide; I D Graham; Mark N Levine; Kathleen I Pritchard; William K Evans; Jean Maroun; D I Hodson; M S Carey; Donald H Cowan
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1226-31.
1998: Frederick R Rickles; Mark N Levine
Venous thromboembolism in malignancy and malignancy in venous thromboembolism.
Haemostasis 1998;28 Suppl 3():43-9.
1998: Anna Falanga; Mark N Levine; R Consonni; G Gritti; F Delaini; E Oldani; J A Julian; Tiziano Barbui
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial.
Thrombosis and haemostasis 1998;79(1):23-7.
1997: Timothy J Whelan; E Ann Mohide; Andrew R Willan; A Arnold; M Tew; S Sellick; A Gafni; Mark N Levine
The supportive care needs of newly diagnosed cancer patients attending a regional cancer center.
Cancer 1997;80(8):1518-24.
1997: Timothy J Whelan; B M Lada; E Laukkanen; F E Perera; W E Shelley; Mark N Levine
Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group.
Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC 1997;1(3):228-40.
1997: Mark N Levine
Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.
Thrombosis and haemostasis 1997;78(1):133-6.
1997: Kathleen I Pritchard; A H Paterson; S Fine; N A Paul; Benny Zee; Lois E Shepherd; Hakam Abu-Zahra; J Ragaz; Margaret A Knowling; Mark N Levine; S Verma; D Perrault; P L Walde; Vivien H C Bramwell; M Poljicak; Norman F Boyd; David Warr; BD Norris; D Bowman; G R Armitage; H Weizel; R A Buckman
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2302-11.
1997: Doug Mirsky; S E O'Brien; David R McCready; TE Newman; Timothy J Whelan; Mark N Levine
Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group.
Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC 1997;1(1):10-7.
1997: George Browman; Mark N Levine; I Graham; Timothy Whelan; Carol Sawka; Kathleen I Pritchard; Alejandro R Jadad; TE Newman
The clinical practice guideline: an evolving health care technology.
Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC 1997;1(1):7-8.
1996: E Ann Mohide; T J Whelan; D Rath; A Gafni; Andrew R Willan; D Czukar; I B Campbell; G S Okawara; M Neimanis; Mark N Levine
A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre.
British journal of cancer 1996;73(12):1588-93.
1996: Mark N Levine; M Gent; J Hirsh; Jeffrey Weitz; Alexander G G Turpie; P Powers; J Neemeh; Andrew R Willan; P Skingley
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
Archives of internal medicine 1996;156(8):851-6.
1996: M Gent; J Hirsh; J S Ginsberg; P J Powers; Mark N Levine; W H Geerts; R M Jay; J Leclerc; J A Neemeh; Alexander G G Turpie
Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
Circulation 1996;93(1):80-4.
1995: Mark N Levine; J Hirsh; M Gent; Alexander G G Turpie; Jeffrey Weitz; Jeffrey Ginsberg; W Geerts; J LeClerc; J Neemeh; P Powers
Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
Thrombosis and haemostasis 1995;74(2):606-11.
1995: Mark N Levine
Thrombolytic therapy for venous thromboembolism. Complications and contraindications.
Clinics in chest medicine 1995;16(2):321-8.
1995: Theodore E Warkentin; Mark N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; John G Kelton
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
The New England journal of medicine 1995;332(20):1330-5.
1995: T J Whelan; Mark N Levine; A Gafni; H Lukka; E Ann Mohide; M Patel; David Streiner
Breast irradiation postlumpectomy: development and evaluation of a decision instrument.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(4):847-53.
1995: George Browman; Mark N Levine; E Ann Mohide; R S Hayward; Kathleen I Pritchard; A Gafni; A Laupacis
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):502-12.
1995: Nancy M Heddle; L Klama; John G Kelton; R Meyer; Irwin Walker; L Dickson; S Chambers; Mark N Levine
The use of anti-D to improve post-transfusion platelet response: a randomized trial.
British journal of haematology 1995;89(1):163-8.
1994: George Browman; C Cripps; D I Hodson; Libni Eapen; J Sathya; Mark N Levine
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2648-53.
1994: J S Ginsberg; M T Nurmohamed; M Gent; Betsy MacKinnon; J Sicurella; Patrick Brill-Edwards; Mark N Levine; Akbar Panju; P Powers; P Stevens
Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.
Circulation 1994;90(5):2385-9.
1994: Mark N Levine; J Hirsh; M Gent; Alexander G G Turpie; M Cruickshank; Jeffrey Weitz; D Anderson; M Johnson
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Archives of internal medicine 1994;154(1):49-56.
1994: J Hirsh; Mark N Levine
Low molecular weight heparin: laboratory properties and clinical evaluation. A review.
The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 1994;(571):9-22.
1993: D R Anderson; Bernie J O'Brien; Mark N Levine; R Roberts; Philip S Wells; J Hirsh
Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.
Annals of internal medicine 1993;119(11):1105-12.
1993: George Browman; Mark N Levine; D I Hodson; J Sathya; R Russell; P Skingley; C Cripps; Libni Eapen; A Girard
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):863-72.
1993: George Browman; G Wong; I Hodson; J Sathya; R Russell; L McAlpine; P Skingley; Mark N Levine
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.
The New England journal of medicine 1993;328(3):159-63.
1993: Mark N Levine; Vivien H C Bramwell; K Pritchard; D Perrault; Brian Findlay; Hakam Abu-Zahra; David Warr; Andrew Arnold; J Skillings
The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer.
Drugs 1993;45 Suppl 2():51-9; discussion 58-9.
1992: Nancy M Heddle; W T Brox; L N Klama; L L Dickson; Mark N Levine
A randomized trial on the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty.
Transfusion 1992;32(8):742-6.
1992: Alexander G G Turpie; M Gent; R Côte; Mark N Levine; J S Ginsberg; P J Powers; J Leclerc; W Geerts; R Jay; J Neemeh
A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
Annals of internal medicine 1992;117(5):353-7.
1992: Mark N Levine; A Gafni; B Markham; D MacFarlane
A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer.
Annals of internal medicine 1992;117(1):53-8.
1992: Edward Young; M Prins; Mark N Levine; J Hirsh
Heparin binding to plasma proteins, an important mechanism for heparin resistance.
Thrombosis and haemostasis 1992;67(6):639-43.
1992: A M Arnold; George Browman; Mark N Levine; T D'Souza; B Johnstone; P Skingley; L Turner-Smith; R Cayco; L Booker; M Newhouse
The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial.
British journal of cancer 1992;65(5):737-43.
1992: Mark N Levine; Vivien H C Bramwell; Hakam Abu-Zahra; M D Goodyear; Andrew Arnold; Brian Findlay; J Skillings; M Gent
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
British journal of cancer 1992;65(1):130-2.
1992: Mark N Levine; Vivien H C Bramwell; K Pritchard; D Perrault; Brian Findlay; Hakam Abu-Zahra; David Warr; Andrew Arnold; J Skillings
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):37-43.
1992: L M Reyno; Mark N Levine; P Skingley; Andrew Arnold; Hakam Abu-Zahra
Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):21-3.
1991: Mark N Levine
Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism.
Chest 1991;99(4 Suppl):128S-134S.
1991: Mark N Levine; J Hirsh; M Gent; Alexander G G Turpie; J Leclerc; P J Powers; R M Jay; J Neemeh
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.
Annals of internal medicine 1991;114(7):545-51.
1991: Mark N Levine; George Browman; M Gent; R Roberts; M Goodyear
When is a prognostic factor useful? A guide for the perplexed.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(2):348-56.
1991: M K Cruickshank; Mark N Levine; J Hirsh; R Roberts; M Siguenza
A standard heparin nomogram for the management of heparin therapy.
Archives of internal medicine 1991;151(2):333-7.
1990: Mark N Levine; M Gent; W M Hryniuk; Vivien H C Bramwell; Hakam Abu-Zahra; S DePauw; Andrew Arnold; Brian Findlay; L Levin; J Skillings
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1217-25.
1990: Alexander G G Turpie; Mark N Levine; J Hirsh; J S Ginsberg; M Cruickshank; R Jay; M Gent
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.
Chest 1990;97(4 Suppl):172S-175S.
1990: Mark N Levine; Jeffrey Weitz; Alexander G G Turpie; Maureen Andrew; M Cruickshank; J Hirsh
A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
Chest 1990;97(4 Suppl):168S-171S.
1990: George Browman; Andrew Arnold; Mark N Levine; T D'Souza; L M Turner-Smith; R Cayco; B Johnstone; R Birse
Use of screening phase data to evaluate observer variation of sputum cytodiagnosis as an outcome measure in a chemoprevention trial.
Cancer research 1990;50(4):1216-9.
1990: George Browman; M D Goodyear; Mark N Levine; R Russell; Stuart Archibald; J E Young
Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(2):203-8.
1990: A M Arnold; George Browman; B Johnstone; P Skingley; L Booker; Mark N Levine
Chemoprevention for lung cancer--evidence for a high degree of compliance.
Cancer detection and prevention 1990;14(5):521-5.
1989: M K Cruickshank; Mark N Levine; J Hirsh; Alexander G G Turpie; P Powers; R Jay; M Gent
An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery.
Thrombosis and haemostasis 1989;62(3):830-4.
1989: Mark N Levine; A Planes; J Hirsh; M Goodyear; N Vochelle; M Gent
The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement.
Thrombosis and haemostasis 1989;62(3):940-4.
1989: A G Fennerty; Mark N Levine
Non-biological factors in day to day variation of heparin requirements.
BMJ (Clinical research ed.) 1989;299(6706):1012-3.
1989: George Browman; Andrew Arnold; L Booker; B Johnstone; P Skingley; Mark N Levine
Etretinate blood levels in monitoring of compliance and contamination in a chemoprevention trial.
Journal of the National Cancer Institute 1989;81(10):795-8.
1989: J S Ginsberg; J Hirsh; D C Turner; Mark N Levine; R Burrows
Risks to the fetus of anticoagulant therapy during pregnancy.
Thrombosis and haemostasis 1989;61(2):197-203.
1988: Mark N Levine; G H Guyatt; M Gent; S De Pauw; M D Goodyear; W M Hryniuk; Andrew Arnold; Brian Findlay; J R Skillings; Vivien H C Bramwell
Quality of life in stage II breast cancer: an instrument for clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(12):1798-810.
1988: Jeffrey I Weitz; M K Cruickshank; B Thong; B Leslie; Mark N Levine; J Ginsberg; T Eckhardt
Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.
The Journal of clinical investigation 1988;82(5):1700-7.
1988: George Browman; Mark N Levine; M D Goodyear; R Russell; Stuart Archibald; B S Jackson; J E Young; V Basrur; C Johanson
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(6):963-8.
1988: Mark N Levine; M Gent; J Hirsh; Andrew Arnold; M D Goodyear; W Hryniuk; S De Pauw
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.
The New England journal of medicine 1988;318(7):404-7.
1988: Mark N Levine; J Hirsh
An overview of clinical trials of low molecular weight heparin fractions.
Acta chirurgica Scandinavica. Supplementum 1988;543():73-9.
1988: Mark N Levine; J Hirsh
Clinical use of low molecular weight heparins and heparinoids.
Seminars in thrombosis and hemostasis 1988;14(1):116-25.
1987: Mark N Levine; J Hirsh
Sample size in the planning and interpretation of clinical trials.
Thrombosis and haemostasis 1987;58(4):953-6.
1987: J Hirsh; Mark N Levine
The optimal intensity of oral anticoagulant therapy.
JAMA : the journal of the American Medical Association 1987;258(19):2723-6.
1987: Alexander G G Turpie; Mark N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; H N Magnani; R D Hull; M Gent
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
Lancet 1987;1(8532):523-6.
1986: Alexander G G Turpie; Mark N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; Russell D Hull; M Gent
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.
The New England journal of medicine 1986;315(15):925-9.
1983: George Browman; Stuart Archibald; J E Young; W M Hryniuk; R Russell; K Kiehl; Mark N Levine
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1983;1(12):787-92.